Making pharmaceutical healthcare more efficient and sustainable
Our focus lies on prevention and treatment of disease by medicines, including drugs and vaccines, considering effects on quality of life and costs, clinical management of drug therapy and drug safety, all explicitly as part of healthy ageing.
Through our research we increase our knowledge on the use and effects of drugs and vaccines, particularly in vulnerable populations, and improve the quality of life and healthy ageing. Our findings support pharmaceutical decision making from regulatory approval, reimbursement to optimal medication use in daily practice.
To increase our knowledge and effectively disseminate it, we collaborate across local and international networks (e.g. EU COST Action, MAECON, H2020 STARS) and with practice and policy oriented organisations (e.g. KNMP, CBG-MEB, LAREB). This strategy has contributed to
- drug regulatory decision making, e.g. focusing on the use of real world data and on patient involvement,
- the improvement and implementation of new methods in pharmacovigilance, including the use of patient-reported outcomes
- national practice guidelines, e.g. recommendations for implementing medication deprescribing in elderly patients.